Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

The biology of incretin hormones

Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works

Phlorizin: a review

Ehrenkranz, J. R. L., Lewis, N., Kahn, C. R., & Roth, J. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 938 · see citing works

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner‐Weir, S., Habener, J. F., & Egan, J. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576 · see citing works

Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia

Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner‐Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 379 · see citing works

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

Fehmann, H. C., & Habener, J. F. (1992) · Endocrinology · doi:10.1210/endo.130.1.1309325 · Cited by 337 · see citing works

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects

Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 308 · see citing works

Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression

Kim, S., Winter, K. D., Nian, C., Tsuneoka, M., Koda, Y., & McIntosh, C. H. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500540200 · Cited by 241 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Is a Growth Factor for β (INS-1) Cells by Pleiotropic Signaling

Trümper, A., Trümper, K., Trusheim, H., Arnold, R., Göke, B., & Hörsch, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.9.0688 · Cited by 238 · see citing works

Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats

Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R. W., Parkhouse, W. S., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232 · see citing works

The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide—Regardless of Etiology and Phenotype

Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T. W., Pedersen, O. B., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 230 · see citing works

The Insulinotropic Action of Gastric Inhibitory Polypeptide in the Perfused Isolated Rat Pancreas

Pederson, R. A., & Brown, J. C. (1976) · Endocrinology · doi:10.1210/endo-99-3-780 · Cited by 210 · see citing works

Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats

Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208 · see citing works

Genetic Regulation of Metabolic Pathways in β-Cells Disrupted by Hyperglycemia

Laybutt, D. R., Sharma, A., Sgroi, D. C., Gaudet, J., Bonner‐Weir, S., & Weir, G. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111751200 · Cited by 202 · see citing works

Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells

Zhou, Y.-T., Shimabukuro, M., Wang, M.-Y., Lee, Y., Higa, M., Milburn, J. L., Newgard, C. B., & Unger, R. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8898 · Cited by 173 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Promotes β-(INS-1) Cell Survival via Cyclic Adenosine Monophosphate-Mediated Caspase-3 Inhibition and Regulation of p38 Mitogen-Activated Protein Kinase

Ehses, J. A., Casilla, V. R., Doty, T., Pospisilik, J. A., Winter, K. D., Demuth, H., Pederson, R. A., & McIntosh, C. H. S. (2003) · Endocrinology · doi:10.1210/en.2002-0068 · Cited by 159 · see citing works

Glucose Down-regulates the Expression of the Peroxisome Proliferator-activated Receptor-α Gene in the Pancreatic β-Cell

Roduit, R., Morin, J., Massé, F., Segall, L., Roche, E., Newgard, C. B., Assimacopoulos‐Jeannet, F., & Prentki, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006001200 · Cited by 158 · see citing works

Antecedent Hyperglycemia, Not Hyperlipidemia, Is Associated With Increased Islet Triacylglycerol Content and Decreased Insulin Gene mRNA Level in Zucker Diabetic Fatty Rats

Harmon, J. S., Gleason, C. E., Tanaka, Y., Poitout, V., & Robertson, R. P. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2481 · Cited by 140 · see citing works

Long-Term Treatment With Dipeptidyl Peptidase IV Inhibitor Improves Hepatic and Peripheral Insulin Sensitivity in the VDF Zucker Rat

Pospisilik, J. A., Stafford, S. G., Demuth, H., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 138 · see citing works

Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets

Lalloyer, F., Vandewalle, B., Percevault, F., Torpier, G., Kerr-Conte, J. A., Oosterveer, M. H., Paumelle, R., Fruchart, J., Kuipers, F., Pattou, F. N., et al. (2006) · Diabetes · doi:10.2337/db06-0016 · Cited by 115 · see citing works

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 111 · see citing works

A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells

Lynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0243fje · Cited by 91 · see citing works

Recent Developments in Inhibiting Cysteine and Serine Proteases

Demuth, H. (1990) · Journal of enzyme inhibition · doi:10.3109/14756369009030375 · Cited by 87 · see citing works

Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

Almind, K., Ambye, L., Urhammer, S. A., Hansen, T. F., Echwald, S. M., Holst, J. J., Gromada, J., Thorens, B., & Pedersen, O. B. (1998) · Diabetologia · doi:10.1007/s001250051051 · Cited by 68 · see citing works

Identification of Two Missense Mutations in the GIP Receptor Gene: A Functional Study and Association Analysis with NIDDM: No Evidence of Association with Japanese NIDDM Subjects

Kubota, A., Yamada, Y., HAYAMI, T., Yasuda, K., Someya, Y., Ihara, Y., Kagimoto, S., Watanabe, R., Taminato, T., Tsuda, K., et al. (1996) · Diabetes · doi:10.2337/diab.45.12.1701 · Cited by 62 · see citing works

Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats

Tseng, C., Boylan, M. O., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e661 · Cited by 56 · see citing works

Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus

McIntosh, C. H. S., Demuth, H., Kim, S.-J., Pospisilik, J. A., & Pederson, R. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.12.013 · Cited by 54 · see citing works

Characterization of GIP(1–30) and GIP(1–42) as stimulators of proinsulin gene transcription

Fehmann, H. C., & Göke, B. (1995) · Peptides · doi:10.1016/0196-9781(95)00090-7 · Cited by 50 · see citing works

Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide

Hinke, S., Pauly, R., Ehses, J. A., Kerridge, P., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650281 · Cited by 24 · see citing works

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works

GIP and GLP-1, the two incretin hormones: Similarities and differences

Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · see citing works

Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium

Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683 · see citing works

Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs

Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 502 · see citing works

The New Biology and Pharmacology of Glucagon

Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · see citing works

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

Åhrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 417 · see citing works

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · see citing works

The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update

Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · see citing works

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes

Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280 · see citing works

Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls

Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272 · see citing works

Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

Shu, L., Matveyenko, A. V., Kerr-Conte, J. A., Cho, J., McIntosh, C. H. S., & Maedler, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp178 · Cited by 269 · see citing works

The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones

Meek, C. L., Lewis, H. B., Reimann, F. M., Gribble, F. M., & Park, A. J. (2015) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 268 · see citing works

Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A

Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267 · see citing works

The incretin system in healthy humans: The role of GIP and GLP-1

Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248 · see citing works

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists

Holst, J. J., & Rosenkilde, M. M. (2020) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/clinem/dgaa327 · Cited by 207 · see citing works

Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation

Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 189 · see citing works

Chapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 172 · see citing works

Potential Hormone Mechanisms of Bariatric Surgery

Dimitriadis, G. K., Randeva, M. S., & Miras, A. D. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0276-5 · Cited by 168 · see citing works

Glucagon-like peptide-1, glucose homeostasis and diabetes

Holst, J. J., Deacon, C. F., Vilsbøll, T., Krarup, T., & Madsbad, S. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.01.003 · Cited by 160 · see citing works

New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics

Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158 · see citing works

GPR119 agonists for the treatment of type 2 diabetes

Jones, R. M., Leonard, J. N., Buzard, D. J., & Lehmann, J. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903153878 · Cited by 154 · see citing works

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · see citing works

The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications

Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works

The intestine as an endocrine organ and the role of gut hormones in metabolic regulation

Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144 · see citing works

Targeting the glucagon receptor family for diabetes and obesity therapy

Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 142 · see citing works

Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity

Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 126 · see citing works

Incretins: their physiology and application in the treatment of diabetes mellitus

Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121 · see citing works

Reduced Glucose Tolerance and Insulin Resistance Induced by Steroid Treatment, Relative Physical Inactivity, and High-Calorie Diet Impairs the Incretin Effect in Healthy Subjects

Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0119 · Cited by 109 · see citing works

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

Åhrén, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.003 · Cited by 108 · see citing works

Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes.

Oduori, O. S., Murao, N., Shimomura, K., Takahashi, H., Zhang, Q., Dou, H.-Q., Sakai, S., Minami, K., Chanclón, B., Guida, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140046 · Cited by 85 · see citing works

Therapeutic potential for GIP receptor agonists and antagonists

Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 105 · see citing works

A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control

Widenmaier, S. B., Kim, S. J., Yang, G. K., Reyes, T. D. L., Nian, C., Asadi, A., Seino, Y., Kieffer, T. J., Kwok, Y. N., & McIntosh, C. H. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009590 · Cited by 102 · see citing works

Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

Picatoste, B., Ramírez, E., Caro‐Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078330 · Cited by 101 · see citing works

The role of GIP in α-cells and glucagon secretion

EL, K. M., & Campbell, J. E. (2019) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 97 · see citing works

Control of insulin secretion by GLP-1

Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 96 · see citing works

Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists=antagonists?

Killion, E. A., Lu, S.-C., Fort, M., Yamada, Y., Véniant, M. M., & Lloyd, D. J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz002 · Cited by 94 · see citing works

Incretins in obesity and diabetes

Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP)

Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 99 · see citing works

K-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease

Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 93 · see citing works

GIP and Bariatric Surgery

Rao, R. S., & Kini, S. U. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0305-x · Cited by 93 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · see citing works

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism

Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420912972 · Cited by 85 · see citing works

Mechanisms of Glucose Homeostasis After Roux-en-Y Gastric Bypass Surgery in the Obese, Insulin-Resistant Zucker Rat

Meirelles, K., Ahmed, T., Culnan, D. M., Lynch, C. J., Lang, C. H., & Cooney, R. N. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181904af0 · Cited by 81 · see citing works

GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function

Zaïmia, N., Obeid, J., Varrault, A., Sabatier, J., Broca, C., Gilon, P., Costes, S., Bertrand, G., & Ravier, M. A. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113326 · Cited by 78 · see citing works

Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options

Artasensi, A., Mazzolari, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2023) · Molecules · doi:10.3390/molecules28073094 · Cited by 65 · see citing works

Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances

Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 59 · see citing works

Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes

Kang, Z., Deng, Y., Zhou, Y., Fan, R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2012) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 54 · see citing works

Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications

Holst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 71 · see citing works

A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores

Martin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.03.011 · Cited by 53 · see citing works

Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?

Irwin, N., Gault, V. A., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513381 · Cited by 53 · see citing works

GIP analogues and the treatment of obesity-diabetes

Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 51 · see citing works

GIP Contributes to Islet Trihormonal Abnormalities in Type 2 Diabetes

Chia, C. W., Odetunde, J. O., Kim, W., Carlson, O. D., Ferrucci, L., & Egan, J. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3994 · Cited by 51 · see citing works

Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors

Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12395 · Cited by 49 · see citing works

Physiologic and Pharmacologic Modulation of Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Expression in β-Cells by Peroxisome Proliferator–Activated Receptor (PPAR)-γ Signaling

Gupta, D., Peshavaria, M., Monga, N., Jetton, T. L., & Leahy, J. L. (2010) · Diabetes · doi:10.2337/db09-1655 · Cited by 47 · see citing works

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties

Kerr, B. D., Irwin, N., O'Harte, F. P. M., Bailey, C. J., Flatt, P. R., & Gault, V. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.037 · Cited by 44 · see citing works

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

Pathak, N. M., Pathak, V., Gault, V. A., McClean, S., Irwin, N., & Flatt, P. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.021 · Cited by 43 · see citing works

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon

Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity &amp; Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39 · see citing works

Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential

Gault, V. A., Martin, C. M., Flatt, P. R., Parthsarathy, V., & Irwin, N. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0681-0 · Cited by 39 · see citing works

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice

Irwin, N., Hunter, K., Frizzell, N., & Flatt, P. R. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.11.007 · Cited by 38 · see citing works

Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity

Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 38 · see citing works

Molecular interactions of full-length and truncated GIP peptides with the GIP receptor – A comprehensive review

Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & ROSENKILDE, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37 · see citing works

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes

Gault, V. A., Kerr, B. D., Irwin, N., & Flatt, P. R. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.03.011 · Cited by 36 · see citing works

Sodium‐glucose cotransporter‐2 inhibition improves incretin sensitivity of pancreatic β‐cells in people with type 2 diabetes

Ahn, C. H., Oh, T. J., Kwak, S. H., & Cho, Y. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13081 · Cited by 33 · see citing works

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus

Sugimoto, T. (2014) · Medical Science Monitor · doi:10.12659/msm.890989 · Cited by 33 · see citing works

An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice

Hasib, A., Ng, M. T., Gault, V. A., Khan, D., Parthsarathy, V., Flatt, P. R., & Irwin, N. (2016) · Diabetologia · doi:10.1007/s00125-016-4186-y · Cited by 33 · see citing works

Recent advances of GIP and future horizons

Holst, J. J., & ROSENKILDE, M. M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170230 · Cited by 33 · see citing works

A novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents

Tatarkiewicz, K., Hargrove, D. M., Jodka, C. M., Gedulin, B. R., Smith, P. A., Hoyt, J. A., Lwin, A. N., Collins, L., Мамедова, Л. Т., Levy, O. E., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12181 · Cited by 32 · see citing works

Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin

Martin, C. M., Parthsarathy, V., Hasib, A., Ng, M. T., McClean, S., Flatt, P. R., Gault, V. A., & Irwin, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152818 · Cited by 32 · see citing works

Internalization and desensitization of the human glucose-dependent-insulinotropic receptor is affected by N-terminal acetylation of the agonist

Ismail, S., Dubois-Vedrenne, I., Laval, M., Tikhonova, I. G., D’Angelo, R., Sanchez, C., Clerc, P., Ghérardi, M.-J., Gigoux, V., Magnan, R., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.001 · Cited by 31 · see citing works

Incretin actions and consequences of incretin‐based therapies: lessons from complementary animal models

Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 31 · see citing works

Aging-related modifications to G protein-coupled receptor signaling diversity

van Gastel, J., Leysen, H., Boddaert, J., Vangenechten, L., Luttrell, L. M., Martin, B., & Maudsley, S. R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107793 · Cited by 31 · see citing works

Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract

Adriaenssens, A. E., Reimann, F. M., & Gribble, F. M. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170047 · Cited by 35 · see citing works

Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions

Hasib, A. (2020) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551420905844 · Cited by 29 · see citing works

Glucose-Dependent Insulinotropic Polypeptide—A Postprandial Hormone with Unharnessed Metabolic Potential

Guccio, N., Gribble, F. M., & Reimann, F. M. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-113625 · Cited by 29 · see citing works

Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1–30) expression is upregulated in diabetes and PEGylated GIP(1–30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice

Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Atageldiyeva, K. K., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., & Haneda, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3842-y · Cited by 27 · see citing works

The emerging role of the intestine in metabolic diseases

Bradley, W. D., Zwingelstein, C., & Rondinone, C. M. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.578651 · Cited by 24 · see citing works

Effects of GLP-1 and GIP on Islet Function in Glucose-Intolerant, Pancreatic-Insufficient Cystic Fibrosis

Nyirjesy, S. C., Peleckis, A. J., Eiel, J. N., Gallagher, K., Doliba, A., Tami, A., Flatt, A. J., León, D. D. D., Hadjiliadis, D., Sheikh, S., et al. (2022) · Diabetes · doi:10.2337/db22-0399 · Cited by 24 · see citing works

Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels

Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22 · see citing works

The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice

Hutch, C. R., Roelofs, K. J., Haller, A. M., Sorrell, J. E., Leix, K., D’Alessio, D. D., Augustin, R., Seeley, R. J., Klein, T., & Sandoval, D. A. (2019) · Diabetologia · doi:10.1007/s00125-019-4963-5 · Cited by 22 · see citing works

Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus

Kosiński, M., Knop, F. K., Vedtofte, L., Grycewiczv, J., Swierzewska, P., Cypryk, K., & Vilsbøll, T. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.08.002 · Cited by 22 · see citing works

Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice

Millar, P., Pathak, V., Moffett, R. C., Pathak, N., Bjourson, A. J., O’Kane, M., Flatt, P. R., & Gault, V. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.019 · Cited by 22 · see citing works

Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications

Holst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/j.2040-4603.2019.tb00092.x · Cited by 19 · see citing works

Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER

Gigoux, V., & Fourmy, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00050 · Cited by 19 · see citing works

Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients

Škrha, J., Hilgertová, J., Jarolimkova, M., Kunešová, M., & Hill, M. (2010) · Physiological Research · doi:10.33549/physiolres.931893 · Cited by 19 · see citing works

Effects of chronic exposure of clonal β‐cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP ‐1

Pathak, V., Vasu, S., Flatt, P. R., & Irwin, N. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12227 · Cited by 17 · see citing works

Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice

Fushimi, Y., Obata, A., Sanada, J., Nogami, Y., Ikeda, T., Yamasaki, Y., Obata, Y., Shimoda, M., Nakanishi, S., Mune, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94896-w · Cited by 17 · see citing works

Antibodies in metabolic diseases

Ahrens, B. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.022 · Cited by 17 · see citing works

Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice

Prévost, G., Arabo, A., Solliec, M.-A. L., Bons, J., Picot, M., Maucotel, J., Berrahmoune, H., Mehdi, M. E., Cherifi, S., Bénani, A., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00540.2018 · Cited by 16 · see citing works

Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet

Lewandowski, S. L., EL, K. M., & Campbell, J. E. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00360.2023 · Cited by 14 · see citing works

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

Ciardullo, S., Morieri, M. L., DANIELE, G., Fiorentino, T. V., Mezza, T., Tricò, D., Consoli, A., Prato, S. D., Giorgino, F., Piro, S., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02300-6 · Cited by 15 · see citing works

Short and long-term effects of high-intensity interval training applied alone or with whole-body cryostimulation on glucose homeostasis and myokine levels in overweight to obese subjects

Flis, M., Rodziewicz-Flis, E. A., Micielska, K., Kortas, J. A., Jaworska, J., Borkowska, A., Sansoni, V., Perego, S., Lombardi, G., & Ziemann, E. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5015 · Cited by 13 · see citing works

Changes in Gastric Inhibitory Polypeptide (GIP) After Roux-en-Y Gastric Bypass in Obese Patients: a Meta-analysis

Gao, Z., Yang, J., Liang, Y., Yang, S., Zhang, T., Gong, Z., & Li, M. (2022) · Obesity Surgery · doi:10.1007/s11695-022-05959-4 · Cited by 12 · see citing works

Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice

McShane, L. M., Irwin, N., O’Flynn, D., Franklin, Z. J., Hewage, C. M., & O'Harte, F. P. M. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0463 · Cited by 12 · see citing works

β‐Cell biology of insulin secretion

Seino, D. M. S. S., Shibasaki, T., & Minami, K. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch7 · Cited by 16 · see citing works

Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract

Adriaenssens, A. E., Reimann, F. M., & Gribble, F. M. (2018) · Comprehensive physiology · doi:10.1002/j.2040-4603.2018.tb00048.x · Cited by 9 · see citing works

Gut Peptide Agonism in the Treatment of Obesity and Diabetes

Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 9 · see citing works

Correction: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

Picatoste, B., Ramírez, E., Caro‐Vadillo, A., Iborra, C., Egido, J., n, J. T., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287 · Cited by 9 · see citing works

Polyagonists in Type 2 Diabetes Management

Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8 · see citing works

Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes

Ahn, C. H., Oh, T. J., Min, S. H., & Cho, Y. M. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.103 · Cited by 8 · see citing works

Regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in the pancreatic β-cell

Lynn, F. C. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0091323

Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats

Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208 · see citing works

A characterization of glucose-induced downregulation of the glucose dependent insulinotropic polypeptide receptor (GIPR)

Olver, A. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0101080

Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia

Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner‐Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 379 · see citing works

A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells

Lynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0243fje · Cited by 91 · see citing works